PE20030859A1 - Composiciones de medicamentos sobre la base de agentes anticolinergicos y de agentes inhibidores de la cinasa del egfr - Google Patents

Composiciones de medicamentos sobre la base de agentes anticolinergicos y de agentes inhibidores de la cinasa del egfr

Info

Publication number
PE20030859A1
PE20030859A1 PE2003000163A PE2003000163A PE20030859A1 PE 20030859 A1 PE20030859 A1 PE 20030859A1 PE 2003000163 A PE2003000163 A PE 2003000163A PE 2003000163 A PE2003000163 A PE 2003000163A PE 20030859 A1 PE20030859 A1 PE 20030859A1
Authority
PE
Peru
Prior art keywords
amino
egfr
agents
etoxy
vinylcarbonyl
Prior art date
Application number
PE2003000163A
Other languages
English (en)
Spanish (es)
Inventor
Birgit Jung
Michael P Pieper
Michel Pairet
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of PE20030859A1 publication Critical patent/PE20030859A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PE2003000163A 2002-02-16 2003-02-14 Composiciones de medicamentos sobre la base de agentes anticolinergicos y de agentes inhibidores de la cinasa del egfr PE20030859A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10206505A DE10206505A1 (de) 2002-02-16 2002-02-16 Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und EGFR-Kinase-Hemmern

Publications (1)

Publication Number Publication Date
PE20030859A1 true PE20030859A1 (es) 2003-11-18

Family

ID=27635037

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000163A PE20030859A1 (es) 2002-02-16 2003-02-14 Composiciones de medicamentos sobre la base de agentes anticolinergicos y de agentes inhibidores de la cinasa del egfr

Country Status (21)

Country Link
EP (1) EP1478398B1 (enExample)
JP (1) JP2005517039A (enExample)
KR (1) KR20040083519A (enExample)
CN (1) CN1633305A (enExample)
AR (1) AR038494A1 (enExample)
AT (1) ATE430581T1 (enExample)
AU (1) AU2003206881B2 (enExample)
BR (1) BR0307703A (enExample)
CA (1) CA2476127C (enExample)
CO (1) CO5611134A2 (enExample)
DE (2) DE10206505A1 (enExample)
ES (1) ES2326968T3 (enExample)
MX (1) MXPA04007813A (enExample)
NZ (1) NZ535166A (enExample)
PE (1) PE20030859A1 (enExample)
PL (1) PL369736A1 (enExample)
RU (1) RU2004127869A (enExample)
TW (1) TW200400036A (enExample)
UY (1) UY27670A1 (enExample)
WO (1) WO2003068264A1 (enExample)
ZA (1) ZA200404787B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10230751A1 (de) * 2002-07-09 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und EGFR-Kinase-Hemmern
WO2005026150A1 (en) 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
DE102004001607A1 (de) * 2004-01-09 2005-08-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen auf der Basis von Scopin- oder Tropensäureestern mit EGFR-Kinase-Hemmern
US20060035893A1 (en) * 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
WO2007029251A2 (en) * 2005-09-06 2007-03-15 T.K. Signal Ltd. Polyalkylene glycol derivatives of 4- (phenylamino)quinazolines useful as irreversible inhibitors of epidermal gr0wth fact0r receptor tyrosine kinase
KR100832593B1 (ko) * 2005-11-08 2008-05-27 한미약품 주식회사 신호전달 저해제로서의 퀴나졸린 유도체 및 이의 제조방법
WO2010054285A2 (en) 2008-11-10 2010-05-14 National Health Research Institutes Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
US20120220557A1 (en) * 2011-02-17 2012-08-30 Chiesi Farmaceutici S.P.A. Liquid propellant-free formulation comprising an antimuscarinic drug
WO2017122205A1 (en) 2016-01-13 2017-07-20 Hadasit Medical Research Services And Development Ltd. Radiolabeled erlotinib analogs and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9622363D0 (en) * 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
DE19911509A1 (de) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10042062A1 (de) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Hertellung

Also Published As

Publication number Publication date
ZA200404787B (en) 2005-08-11
MXPA04007813A (es) 2004-10-15
WO2003068264A1 (de) 2003-08-21
KR20040083519A (ko) 2004-10-02
CO5611134A2 (es) 2006-02-28
CN1633305A (zh) 2005-06-29
RU2004127869A (ru) 2005-08-27
CA2476127A1 (en) 2003-08-21
CA2476127C (en) 2011-06-14
AR038494A1 (es) 2005-01-19
TW200400036A (en) 2004-01-01
DE10206505A1 (de) 2003-08-28
DE50311496D1 (de) 2009-06-18
AU2003206881A1 (en) 2003-09-04
ES2326968T3 (es) 2009-10-22
UY27670A1 (es) 2003-09-30
BR0307703A (pt) 2005-01-04
JP2005517039A (ja) 2005-06-09
PL369736A1 (en) 2005-05-02
AU2003206881B2 (en) 2009-02-26
EP1478398B1 (de) 2009-05-06
EP1478398A1 (de) 2004-11-24
ATE430581T1 (de) 2009-05-15
NZ535166A (en) 2007-01-26

Similar Documents

Publication Publication Date Title
Milne Drugs: synonyms and properties
ES2211108T3 (es) Formulaciones farmaceuticas para aerosoles con dos o mas sustancias activas.
ES2391563T3 (es) Formulaciones en suspensión de aerosol con TG 227 ea como agente propulsor
TWI626059B (zh) 親脂性藥劑之經改良的非經腸胃調配物與用於製造及使用該調配物的方法
WO2004006886A3 (en) Injectable depot formulation comprising crystals of iloperidone
ES2315541T3 (es) Formulaciones que contienen melatonina, ginkgo biloba y biotina.
JP2018021002A (ja) ロキソプロフェンを含有してなる医薬製剤
IL206759A (en) Liquid Pharmaceuticals Containing Follicle Stimulating Hormone (fsh), Pharmaceutical Containers Containing Them, and Methods for Preparing them
DE60308997D1 (de) Formulierungen zur inhalation
BRPI0406905A (pt) Espuma de fosfato de clindamicina
IE61562B1 (en) Azelastine-containing medicaments for application in the nose and/or on the eye
AU2276100A (en) Substituted nitrogen heterocyclic derivatives and pharmaceutical use thereof
CR10114A (es) Composiciones farmacéuticas que comprenden inhibidoras de la hmg coa reductasa (divisional del exp. 6687)
WO2004047833A3 (de) Anthranilsäureamide und deren derivate als kosmetische und pharmazeutische wirkstoffe
BR0009914A (pt) Medicamento, e, usos de um inibidor, e de um ativador de quinase h-sgk humana regulada por volume celular
JP6094388B2 (ja) ペメトレキセドを含む注射用組成物
IL157955A0 (en) Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m toluidide and pvp
WO2007133751A3 (en) Base-stabilized polyorthoester formulations
GT200500111A (es) Acido 2-{[2-(2-metilaminopirimidin-4-il)-1h-indol-5-carbonil]amino}-3-fenilpiridin-2-ilamino)propionico sustancialmente puro como inhibidor de la cinasa ikb
JP2003521518A (ja) モノチオグリセロール、l−システインまたはチオグリコール酸とともにペメトレクストを含む医薬組成物
WO1999012545A3 (en) Medicaments containing acyclovir
AR015668A1 (es) Sal de hemisulfato de (1s,4r)-cis-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il]-2-ciclopenten-1-metanol y formulacion farmaceutica que la contiene
SE0103424D0 (sv) Pharmaceutical formulation
WO2002056876A2 (en) Treatment for snoring
WO2007075572A3 (en) Orally active purine-based inhibitors of heat shock protein 90

Legal Events

Date Code Title Description
FD Application declared void or lapsed